Literature DB >> 15801821

Virtual docking approaches to protein kinase B inhibition.

Martino Forino1, Dawoon Jung, John B Easton, Peter J Houghton, Maurizio Pellecchia.   

Abstract

We examined some in silico approaches to identify Akt (protein kinase B) inhibitors. Experimental validation of selected compounds was achieved using a fluorescence-based enzymatic assay and a substrate phosphorylation assay involving the protein GSK-3. We report on success and failure obtained by using several strategies including FlexX, GOLD, and CSCORE, where the 100-200 top-scoring compounds from a 50000-compound library were experimentally tested. This study led to the identification of low micromolar Akt1 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801821     DOI: 10.1021/jm048962u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma.

Authors:  Elisa Barile; Surya K De; Yongmei Feng; Vida Chen; Li Yang; Ze'ev Ronai; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2013-09-25       Impact factor: 2.817

2.  Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways.

Authors:  Yongmei Feng; Elisa Barile; Surya K De; John L Stebbins; Apple Cortez; Pedro Aza-Blanc; Jessie Villanueva; Meenhard Heryln; Stan Krajewski; Maurizio Pellecchia; Ze'ev A Ronai; Gary G Chiang
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-06       Impact factor: 4.693

3.  Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11.

Authors:  Yongmei Feng; Eric Lau; Marzia Scortegagna; Chelsea Ruller; Surya K De; Elisa Barile; Stan Krajewski; Pedro Aza-Blanc; Roy Williams; Anthony B Pinkerton; Michael Jackson; Lynda Chin; Maurizio Pellecchia; Marcus Bosenberg; Ze'ev A Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2012-11-02       Impact factor: 4.693

4.  BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

Authors:  Supriya Gaitonde; Surya K De; Marianna Tcherpakov; Antimone Dewing; Hongbin Yuan; Megan Riel-Mehan; Stan Krajewski; Gavin Robertson; Maurizio Pellecchia; Ze'ev Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-17       Impact factor: 4.693

Review 5.  How to do an evaluation: pitfalls and traps.

Authors:  Paul C D Hawkins; Gregory L Warren; A Geoffrey Skillman; Anthony Nicholls
Journal:  J Comput Aided Mol Des       Date:  2008-01-23       Impact factor: 3.686

6.  Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma.

Authors:  Ipsita Pal; Kaushik Kumar Dey; Madhuri Chaurasia; Sheetal Parida; Subhayan Das; Y Rajesh; Kulbhushan Sharma; Tamohan Chowdhury; Mahitosh Mandal
Journal:  Tumour Biol       Date:  2015-12-02

7.  Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs).

Authors:  Whitney Beysselance Moro; Zhengrong Yang; Tasha A Kane; Christie G Brouillette; Wayne J Brouillette
Journal:  Bioorg Med Chem Lett       Date:  2009-02-12       Impact factor: 2.823

8.  Computational validation of 3-ammonio-3-(4-oxido- 1H-imidazol-1-ium-5-yl) propane-1, 1-bis (olate) as a potent anti-tubercular drug against mt-MetAP.

Authors:  Abhishek Chowdhury; Shantanu Sen; Pradip Dey; Pankaj Chetia; Anupam Das Talukdar; Amitabha Bhattacharjee; Manabendra Dutta Choudhury
Journal:  Bioinformation       Date:  2012-09-21

9.  Genetics of melanoma.

Authors:  Janet Wangari-Talbot; Suzie Chen
Journal:  Front Genet       Date:  2013-01-25       Impact factor: 4.599

10.  BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.

Authors:  I Pal; S Sarkar; S Rajput; K K Dey; S Chakraborty; R Dash; S K Das; D Sarkar; E Barile; S K De; M Pellecchia; P B Fisher; M Mandal
Journal:  Br J Cancer       Date:  2014-06-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.